BioCryst Pharmaceuticals (NASDAQ:BCRX) Raised to "Strong-Buy" at Wall Street Zen

Key Points

• BioCryst Pharmaceuticals has received an upgrade to a "Strong-Buy" rating from Wall Street Zen, reflecting increased confidence in the stock's performance.
• Analysts from Royal Bank of Canada and Bank of America have set target prices of $13.00 and $15.00 respectively, indicating a positive outlook for the company's shares.
• Institutional investors and hedge funds own 85.88% of BioCryst Pharmaceuticals, showcasing strong interest and investment in the company.

Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX - Free Report) from a buy rating to a strong-buy rating in a report published on Saturday morning.

Other equities analysts have also issued reports about the company. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America increased their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, July 1st. Wedbush increased their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday, June 30th. JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target for the company. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock remained flat at $8.55 during midday trading on Friday. The company had a trading volume of 2,363,782 shares, compared to its average volume of 3,191,850. The company has a market capitalization of $1.79 billion, a PE ratio of -32.88, a P/E/G ratio of 1.40 and a beta of 1.04. BioCryst Pharmaceuticals has a 1 year low of $6.01 and a 1 year high of $11.31. The business's 50 day moving average is $9.76 and its two-hundred day moving average is $8.70.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in BCRX. Lazard Asset Management LLC lifted its position in BioCryst Pharmaceuticals by 68.1% in the 4th quarter. Lazard Asset Management LLC now owns 161,516 shares of the biotechnology company's stock valued at $1,214,000 after acquiring an additional 65,420 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $80,000. Teacher Retirement System of Texas grew its holdings in BioCryst Pharmaceuticals by 25.1% in the fourth quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company's stock worth $438,000 after purchasing an additional 11,711 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at $79,000. Institutional investors and hedge funds own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.